Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum 9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.

GREY:DGCRF - Post Discussion

9342-8530 Quebec Inc > An interesting open..
View:
Post by Dibah42 on Jun 01, 2015 9:49am

An interesting open..

DIAGNOCURE INC (CA: CUR)


        
Real-time  

Last: 0.195   Change: 0.060   Volume: 25,500   Last Trade: 09:42

  Level ll Quote
  Bid     Ask
  Price   Total Size   # of Orders     Price   Total Size   # of Orders
$0.19 2 1   $0.24 10 1
$0.185 2 1   $0.30 10 1
$0.13 60 1   $0.44 6 1
$0.125 6 1   $0.50 20 1
$0.11 52 2   $0.61 0 1
$0.105 120 5   $0.90 0 1
$0.10 40 5   $1.00 2 1
$0.095 28 2   $1.10 10 1
$0.09 8 1   $1.49 25 3
$0.085 10 1   $2.50 10 1
Comment by Timorron on Jun 01, 2015 2:55pm
Someone bought the stock at 0.25$ today. I wonder if it is a cross trade or the reflect of this thin selling side.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities